Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Psychiatry Research
|
December 29, 2020
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial
Henrik Maagensen, Julie R Larsen, Niklas R Jørgensen, et al.
Current Osteoporosis Reports
|
November 28, 2022
The Gut-Bone Axis in Diabetes
Henrik Maagensen, Mads M Helsted, Lærke S Gasbjerg, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 6, 2018
Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose
Henrik Maagensen, Anders E Junker, Niklas R Jørgensen, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 14, 2024
Clinical effects of SGLT2 inhibitors in seven persons with HNF1A-MODY (MODY3)
Henrik Maagensen, Sofie Hædersdal, Jesper Krogh, et al.
Ugeskrift for Laeger
|
July 3, 2026
[Osteodystrophy in chronic liver disease]
Mathilde Svendstrup, Johanne Skov Jensen, Anne Cathrine Baun Thuesen, et al.
Diabetes
|
October 2, 2020
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, et al.
European Journal of Endocrinology
|
August 17, 2022
The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes
Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, et al.
European Journal of Endocrinology
|
December 4, 2021
The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes
Sofie Hædersdal, Asger Lund, Henrik Maagensen, et al.
Diabetes Care
|
July 3, 2025
Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes
Henrik Maagensen, Johanne S Jensen, Stine O Høyerup, et al.
Diabetes Care
|
January 12, 2026
Empagliflozin in HNF1A-MODY (MODY3)-a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
Henrik Maagensen, Stine O Høyerup, Johanne S Jensen, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Psychiatry Research
|
December 29, 2020
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial
Henrik Maagensen, Julie R Larsen, Niklas R Jørgensen, et al.
Current Osteoporosis Reports
|
November 28, 2022
The Gut-Bone Axis in Diabetes
Henrik Maagensen, Mads M Helsted, Lærke S Gasbjerg, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 6, 2018
Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose
Henrik Maagensen, Anders E Junker, Niklas R Jørgensen, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 14, 2024
Clinical effects of SGLT2 inhibitors in seven persons with HNF1A-MODY (MODY3)
Henrik Maagensen, Sofie Hædersdal, Jesper Krogh, et al.
Ugeskrift for Laeger
|
July 3, 2026
[Osteodystrophy in chronic liver disease]
Mathilde Svendstrup, Johanne Skov Jensen, Anne Cathrine Baun Thuesen, et al.
Diabetes
|
October 2, 2020
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, et al.
European Journal of Endocrinology
|
August 17, 2022
The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes
Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, et al.
European Journal of Endocrinology
|
December 4, 2021
The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes
Sofie Hædersdal, Asger Lund, Henrik Maagensen, et al.
Diabetes Care
|
July 3, 2025
Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes
Henrik Maagensen, Johanne S Jensen, Stine O Høyerup, et al.
Diabetes Care
|
January 12, 2026
Empagliflozin in HNF1A-MODY (MODY3)-a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
Henrik Maagensen, Stine O Høyerup, Johanne S Jensen, et al.
Page
of 2